Metronidazole
Active ingredient · 5 therapeutic classes
Sold as Acnil · VAGINYL · NIDAGEL · METROGEL · NORITATE
- Drug class
- Imidazole Derivatives
- Availability
- Prescription and OTC
- Routes
- Oral, Topical, Vaginal, Intravenous
- Markets covered
- 3
- Products on record
- 97
- FDA reports (12 mo)
- 3,085
Overview
Plain-language summary, compiled from the cited regulatory records
Metronidazole is an anti-infective and antiseptic medication used for local oral treatment [1]. It is approved for the symptomatic treatment of Trichomoniasis, specifically infections caused by *T. vaginalis* in both females and males when the presence of the organism is confirmed by laboratory tests [1]. Metronidazole tablets are also indicated for asymptomatic *T. vaginalis* infections in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion [1].
This medication is available under various brand names, including Acnil [1]. In the past 12 months, there have been 3,085 adverse event reports associated with metronidazole [2]. Among the top reported events are off-label use, claims of the drug being ineffective, nausea, headache, and condition aggravation [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 66 | May 22, 2026 |
| CA Canada | Health Canada | 19 | May 29, 2026 |
| US United States | FDA | 12 | April 13, 2026 |
GBUnited Kingdom· MHRA
66 products
Uses
For the topical treatment of Rosacea (inflammatory papulopustules rosacea related).
How to take
CACanada· Health Canada
19 products
Uses
NIDAGEL is indicated for the treatment of bacterial vaginosis (formerly called nonspecific vaginitis, Gardnerella vaginalis or Haemophilus vaginitis) in adult women. A clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogenous vaginal discharge that: a.
5; b. emits a fishy amine odour when mixed with a 10% KOH solution; c. contains clue cells on microscopic examination. , Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and herpes simplex virus should be ruled out.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NIDAGEL and other antibacterial drugs, NIDAGEL should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
USUnited States· FDA
12 products
Uses
INDICATIONS AND USAGE
Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).
Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner.
Drug interactions
Known interactions involving Metronidazole. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 595. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL131590006 · revised May 22, 2026
- [2]Health Canada (DPD) · 02125226 · revised December 29, 2025
- [3]FDA DailyMed · 1277591d-ccf4-42… · revised April 13, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.